Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
660
Trial Sponsor
Clinical Trial Start Date
July 29, 2016
0Primary Completion Date
October 5, 2016
0Study Completion Date
October 1, 2017
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Prevention0
Intervention Type
Biological0
Other0
Intervention Name
VXA-G1.1-NN (low dose) Oral Vaccine Tablet0
VXA Placebo Tablets0
VXA-G1.1-NN (high dose) Oral Vaccine Tablet0
Interventional Trial Phase
Phase 10
Official Name
A Phase 1, Randomized, Double-Blind, Placebo-controlled, Dose-ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-vector Based Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers0
Last Updated
May 31, 2018
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Masked Party
Participant0
Outcomes Assessor0
Investigator0
Care Provider0
Study summary
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Norovirus Vaccine (VXA-G1.1-NN) Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
